KRAS Antibody (OTI2C1)

KRAS, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Showing Publications 1 - 2 of 2.

Publications using NBP2-45536	Applications	Species
Wang D, Wang Q, Wang Y et al. Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides Proceedings of the National Academy of Sciences of the United States of America 2022-07-19 [PMID: 35858356]
Wang Y, Wang D, Jia F et al. Self-Assembled DNA-PEG Bottlebrushes Enhance Antisense Activity and Pharmacokinetics of Oligonucleotides ACS Appl Mater Interfaces 2020-09-30 [PMID: 32936615]

Array NBP2-45536

• KRAS Antibodies
• KRAS ELISA Kits
• KRAS Lysate
• KRAS Proteins